NCT07118592Not yet recruiting
Genetic Architecture of Natriuretic Peptides and Blood Pressure Response
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 5 Aug 2025
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Jun 2030
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- High blood pressure
- NCT number
- NCT07118592
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 1 Sept 2026 to the primary completion date, 1 Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- If taking more than or equal to 2 blood pressure medications at the time of screening
Other illness
- History of uncontrolled hypertension (i.e., Systolic blood pressure more than or equal to 160 mmHg and/or Diastolic blood pressure more than or equal to 100 mmHg)
- Present or past history of major cardiovascular disease including myocardial infarction, angina, cardiac arrhythmia, heart failure, stroke, transient ischemic attack, or seizure.
- History of kidney disease
- History of insulin requiring diabetes
Lab values
- Estimated glomerular filtration rate less than 60ml/min/1.73 m2, albumin creatinine ratio more than or equal to 30 mg/g
- Hepatic transaminase levels more than 3 times the upper limit of normal
- Anemia (men, Hb less than 13 g/dL; women, Hb less than 12 g/dL)
Other
- Body mass index (BMI) more than 45 kg/m2
- Systolic blood pressure more than 180 and/or Diastolic blood pressure more than or equal to 120 mmHg at any point in the study
- Pregnant or breastfeeding individuals
Who the study is looking for
- Age more than or equal to 18 years
- Consenting to collection of genetic material and willing to adhere to study protocol
- Stage I/II Hypertension (Systolic blood pressure: 130-159 and Diastolic blood pressure: 80-99 mm Hg)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.